IDEAYA Biosciences - IDYA Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IDYA shares.
View IDYA analyst ratings or view top-rated stocks.

6 brokers have issued 1 year price objectives for IDEAYA Biosciences' stock. Their IDYA share price forecasts range from $13.00 to $46.00. On average, they anticipate the company's share price to reach $27.50 in the next twelve months. This suggests a possible upside of 116.5% from the stock's current price.
View analysts price targets for IDYA or view top-rated stocks among Wall Street analysts.

IDEAYA Biosciences' stock was trading at $23.64 at the start of the year. Since then, IDYA shares have decreased by 46.3% and is now trading at $12.70.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 21st 2022.
View our IDYA earnings forecast.

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) released its earnings results on Monday, August, 15th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.51) by $0.06. IDEAYA Biosciences had a negative net margin of 225.95% and a negative trailing twelve-month return on equity of 22.38%.

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Boeing (BA), Xeris Biopharma (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA).

(IDYA) raised $70 million in an initial public offering (IPO) on Thursday, May 23rd 2019. The company issued 5,000,000 shares at $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies acted as the underwriters for the IPO.

IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA."

IDEAYA Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Federated Hermes Inc. (5.50%), Price T Rowe Associates Inc. MD (4.88%), Point72 Asset Management L.P. (3.91%), State Street Corp (3.84%), Platinum Investment Management Ltd. (2.39%) and FMR LLC (1.62%). Insiders that own company stock include Bvf Partners L P/Il, Jason Throne, Mark Lackner, Michael P Dillon, Michael P Dillon, Paul A Stone, Value Fund L P Biotechnology and Ventures Iv LP 5Am.
View institutional ownership trends.

Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IDYA stock can currently be purchased for approximately $12.70.

IDEAYA Biosciences (NASDAQ:IDYA) has a market capitalization of $499.19 million and generates $27.94 million in revenue each year. The company earns $-49,760,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.ideayabio.com. The company can be reached via phone at (650) 443-6209 or via email at investor@ideayabio.com.